Injecting engineered immune cells to treat advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of engineered Tumor Infiltrating Lymphocytes (TIL) in patients with advanced malignant solid tumors who have not responded to standard therapies. The approach involves extracting and modifying immune cells from the patient's tumor to enhance their ability to attack cancer cells. Participants will undergo procedures to obtain tumor tissue, which will then be processed to create the GC203 TIL for injection back into the patient. The study aims to provide a new treatment option for patients with various types of advanced cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.

  2\. Patients must be ≥18 and ≤75 years of age at the time of consent. 3. Patients with advanced metastatic solid tumors with clear pathological diagnosis have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy \[including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery\]) , including but not limited to gynecological tumors (ovarian cancer, endometrial cancer, cervical cancer), breast cancer, gastrointestinal Cancer, lung cancer.

  4\. Patients have feasible tissue areas for tumor resection/puncture to generate GC203 TIL, the total volume of the tissue \> 400mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency therapy, oncolytic virus, etc.) or has progressed after local treatment; 5. At least one measurable target lesion before preconditioning, as defined by RECIST1.1.

  6\. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  7\. Patients must have an estimated life expectancy of ≥3 months. 8. Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function:
  * Absolute Neutrophil Count (ANC)≥1.0×10\^9/L;
  * Absolute Lymphocyte Count(ALC)≥0.5×10\^9/L;
  * Platelet≥80×10\^9/L；
  * International Normalized Ratio（INR）≤1.5×ULN;
  * Activated Partial Thromboplastin Time（APTT）≤1.5×ULN;
  * Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min
  * Urinalysis: urine protein less than 2+, or 24-hour urine protein \<1g;
  * Alanine aminotransferase(AST/SGOT) ≤3×ULN;
  * Alanine aminotransferase (ALT/SGPT) ≤3×ULN;
  * Total Bilirubin(TBIL)≤1.5×ULN； 9. Women of child-bearing potential (WCBP), must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.

    10\. Patients must have no contraindications for surgery or biopsy. 11. Patients have good compliance and be able to adhere to research access plans and other protocol requirements.

Exclusion Criteria:

1. Participate in clinical trials of other drugs or biologic therapies within 4 weeks before enrollment;
2. Participants who have had a history of allogeneic T cell therapy; gene engineering autologous cell therapy within 1 years.
3. Patients who have received systemic antitumor therapy within 4 weeks.
4. Patients who have had another primary malignancy within the previous 5 years
5. Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
6. Patients with a history of hypersensitivity to any component of the study drugs
7. Patients who are pregnant or breastfeeding.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Huajun Jin, PhD
• Email: clinicaltrials@juncell.com
• Phone: +8621-69110327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Florida ASCENT Program

  This project will test whether combining the MyCarePulse EHR platform with ASCENT patient navigators helps adults with recent cancer diagnoses in Florida improve food security, diet quality, and confidence in healthy eating compared with standard care.

  Recruiting University of Florida · Gainesville, Florida · NCT07042243

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.